Because there is interest in clinically evaluating systemic delivery of IL13Rα2-CAR T cells for GBM and other IL13Rα2+ solid tumors, including neuroendocrine cancers (22), melanoma (23), ovarian cancer (24), and colorectal cancer (25), we set out to utilize this fully murine platform to preclinically assess the safety and efficacy of intravenously delivered muIL13-BBζ CAR T cells. The gene discussed is IL13RA2; the disease is neuroendocrine carcinoma.